scispace - formally typeset
O

O. Chappey

Researcher at French Institute of Health and Medical Research

Publications -  23
Citations -  2666

O. Chappey is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Endothelium & Glycation. The author has an hindex of 14, co-authored 23 publications receiving 2551 citations.

Papers
More filters
Journal ArticleDOI

Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE.

TL;DR: Findings underscore a central role of NADPH oxidase in AGE-RAGE-mediated generation of ROS and provide a mechanism for altered gene expression in A GE-related disorders.
Journal ArticleDOI

Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats.

TL;DR: Data support the concept that ligation of AGEs by endothelial RAGE induces cellular dysfunction, at least in part by an oxidant-sensitive mechanism, contributing to vascular hyperpermeability in diabetes, and that RAGE is central to this pathologic process.
Journal ArticleDOI

Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications

TL;DR: In this article, the authors hypothesized that formation of advanced glycation end products (AGEs) on the surface of diabetic erythrocytes could mediate their interaction with ECs leading to binding and induction of vascular dysfunction.
Journal ArticleDOI

Advanced glycation end products, oxidant stress and vascular lesions

TL;DR: An attempt to minimize AGE formation and to limit ROI production by an appropriate therapy may result in the reduction or slowing of vascular disease in patients with diabetes mellitus.
Journal ArticleDOI

Recombinant Advanced Glycation End Product Receptor Pharmacokinetics in Normal and Diabetic Rats

TL;DR: This study showed that rR-RAGE was biologically active in vivo and slowly cleared, which suggests it could be considered as a potential therapy in patients with diabetes mellitus.